GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years and as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

GAMMAGARD LIQUID Product Characteristics

Not all intravenous immune globulin (IVIG) formulations are interchangeable^1-3

The final formulation can differ among IVIGs, meaning they are not interchangeable.^1,3 When selecting an IVIG treatment, individual patient characteristics should be considered.^1,3

IVIG treatments are distinct plasma products with patient tolerance differing from one brand to another. Not all IVIG treatments are biologically equivalent, and caution should be used when changing products.^1,3

Patient conditions and risk factors to consider with IVIG administration

Expand Collapse all

Predisposition for renal insufficiency^1,4-6

Patient risk factors (this is not an all-inclusive list)

Diabetes mellitus
Elderly
Hypovolemia
Sepsis
Paraproteinemia
Concomitant therapy with nephrotoxic drugs

IVIG risk factors^1,7

Sodium content	Sugar content	Osmolality	lgA	Volume load

Heart disease^1,8-10

Patient risk factors (this is not an all-inclusive list)

Thromboembolic risk factors
Coronary artery disease
Heart failure
Hypertension
Hyperlipidemia
Cardiovascular risk factors

IVIG risk factors^1,7

Sodium content	Sugar content	Osmolality	lgA	Volume load

Diabetes mellitus⁵

Patient risk factors (this is not an all-inclusive list)

Type 1
Type 2

IVIG risk factors^1,7

Sodium content	Sugar content	Osmolality	lgA	Volume load

Elderly^1,11

Patient risk factors (this is not an all-inclusive list)

Generally considered as >65 years of age

IVIG risk factors^1,7

Sodium content	Sugar content	Osmolality	lgA	Volume load

IgA deficiency¹

Patient risk factors (this is not an all-inclusive list)

IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
All patients, since an IgA concentration that will provoke a reaction is unknown; even trace amounts of IgA present a risk of anaphylaxis

IVIG risk factors^1,7

Sodium content	Sugar content	Osmolality	lgA	Volume load

Volume intake restrictions^1,9

Patient risk factors (this is not an all-inclusive list)

Hyperviscosity risk factors
Cardiac impairment
Renal impairment
Pulmonary edema
Hypertension
Elderly

IVIG risk factors^1,7

Sodium content	Sugar content	Osmolality	lgA	Volume load

GAMMAGARD LIQUID is formulated with patient needs in mind¹²

No added sodium

No added sugar

No preservatives

No latex

Osmolality 240-300 mOsmol/kg, similar to physiologic levels

IgA average
concentration of
37 µg/mL

pH range of 4.6-5.1

Glycine stabilized

GAMMAGARD LIQUID vials.

GAMMAGARD LIQUID is designed
for ease of use

GAMMAGARD LIQUID offers convenient vial size options and storage with no refrigeration required.¹²

See vial and storage info

Review the product characteristics for 12 IVIG treatments

Review the product characteristics of 12 distinct IVIG treatments. Download to save or print for easy reference. Please note, this chart provides product characteristics only and does not imply clinical outcomes.

Download product characteristics chart

Man typing on a keyboard.

Review details for GAMMAGARD LIQUID specific to Primary Immunodeficiency (PI)

PI information

Review details for GAMMAGARD LIQUID specific to Multifocal Motor Neuropathy (MMN)

MMN information